Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04965493
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2021-07-15
Brief Title:
A Trial of Pirtobrutinib LOXO-305 Plus Venetoclax and Rituximab PVR Versus Venetoclax and Rituximab VR in Previously Treated Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma CLLSLL
Sponsor:
Organization:
Eli Lilly and Company
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
600
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: